• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA committee backs first non-opioid medicine to treat opioid withdrawal

March 28, 2018 By Sarah Faulkner

U.S. WorldmedsSpecialty pharma company US WorldMeds said today that an FDA committee voted 11-1 to recommend approval for lofexidine, a selective alpha 2-adrenergic receptor agonist designed to mitigate the symptoms of opioid withdrawal.

The oral drug, which US WorldMeds intends to market under the name Lucemyra, reduces the release of norepinephrine in a person’s brain and suppresses the symptoms of opioid withdrawal. Patients treated with Lucemyra in clinical trials experienced more tolerable withdrawal symptoms and were more likely to finish a seven-day opioid discontinuation program compared to patients taking a placebo, according to US WorldMeds.

If the drug snags FDA approval, it will be the first non-opioid medicine indicated to treat the symptoms of opioid withdrawal, the company touted.

“Today’s favorable recommendation brings us one step closer to providing evidence-based medication, and hope for recovery, to people who want to discontinue opioid use and are struggling with the agonizing symptoms of opioid withdrawal, one of the most powerful factors driving opioid dependence and addictive behaviors,” Dr. Mark Pirner, senior medical director, said in prepared remarks.

The FDA is slated to make a decision about Lucemyra in the second quarter of this year.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance Tagged With: usworldmeds

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS